MSU-42011

Research use only, not for human use.

MSU-42011 is an orally active retinoid X receptor-like (RXR) agonist. It potently inhibits the expression of iNOS, low SREBP-induced and activated RXR, and p-ERK at the protein level.

MSU-42011 is an orally active retinoid X receptor (RXR) agonist. MSU-42011 inhibits the iNOS activity and reduces the expression of p-ERK protein. MSU-42011 has immunomodulatory and antitumor activity.

RT-PCR Cell Line:HepG2 liver cancer cells Concentration:300 nM Incubation Time:8 h Result:SREBP expression ranged from no change to a 1.49-fold induction compared to the vehicle control.

Animal Model:A/J mice (Intraperitoneal injected with the carcinogen ethyl carbamate (0.32 mg/injection) for 8 weeks) Dosage:25 mg/kg Administration:Oral administration; One week after, i.p. every other week for a total of 6 injections with Carboplatin (HY-17393) (50 mg/kg) and paclitaxel (15 mg/kg); for 12 weeksResult:The number and size of detected lung surface tumors increased not in the treatment groupCombines with C/P was most effective in reducing tumor number (67% vs. control), tumor size (76% vs. control), and overall tumor burden (92% vs. control).Animal Model:A/J lung cancer model (Intraperitoneal injected with the carcinogen ethyl carbamate (0.32 mg/injection) for 8 weeks) Dosage:100 mg/kg Administration:Oral administration; After 2 weeks, each mouse was intraperitoneally injected with anti-PD1 and anti-PDL1 antibodies at a rate of 50 μg/mouse, twice a week for a total of 22 times Result:Showed that an increase in the ratio of anti-tumor CD8 T cells to CD4, CD25 T cells resulted in a significant reduction in tumor volume compared to MSU42011 or anti-PD(L)1 antibody alone.

——

Immunology/Inflammation

NOS

NOS | Retinoid Receptor | PERK | Lipid | NO Synthase

——

——

2456434-36-7

382.54

C24H34N2O2

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (326.76 mM; Ultrasonic (<60°C)

N(CC(C)C)(C1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1)C2=CC=C(C(O)=O)C=N2

——

(-20℃)

With Ice Pack

≥ 2 years